![]() |
|
|
College of Pharmacy and Nutrition, University of Saskatchewan, SK, Canada and * Office of Applied Research and Safety Assessment, Center for Food Safety and Applied Nutrition, Food and Drug Administration, Laurel, MD 20708
2To whom correspondence should be addressed. E-mail: susan.whiting{at}usask.ca.
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: vitamin D requirement dietary reference intakes functional indicators calciotropic noncalciotropic
The current (1997) recommended intake for vitamin D
Since the early 1940s, the United States and Canada have set nutrient recommendations for nutrients until the implementation of the Dietary Reference Intakes (DRI)3 process, when, together, recommendations were made (1). Different recommended intakes for vitamin D were proposed by Canada and the United States prior to setting the current recommendations for vitamin D in 1997. Table 1 presents recommended values for adults set by Canada and the United States (19) over the past 4 decades, representing the time for which metabolic pathways of vitamin D were being established. It is notable that the first recommended dietary allowance (RDA) for vitamin D for Americans in 1941 gave the value of 400 IU (i.e., the lower value of a range for infants at the time), for adults only in a footnote that stated "When not available from sunshine, [vitamin D] should be provided up to the minimal amounts recommended for infants" (10). The value of 400 IU (10 µg) was derived from an observation that this amount of vitamin D activity, found in a teaspoon of cod liver oil, was sufficient to prevent rickets (11,12). The RDA for adults for vitamin D has, for the most part, remained at or below the 400 IU (10 µg) level, with Canadian values set much lower, despite being at a higher latitude. Table 1 illustrates that determination of vitamin D requirements and status has been more conjecture than science.
|
Problems with the current recommended intakes for vitamin D
There are several constraints on the current recommended values for vitamin D. The nature of the value, i.e., that it is an AI, specifies that it has limited use. In assessment, this value can be used as a goal for an individual, similar to an RDA value. However, it cannot be used to assess prevalence of inadequacy of groups using the cut point or probability methods. Whereas some AI values may be used in comparison to mean intakes, this is not the case for vitamin D levels; these levels were not based on observed mean intakes of population groups, because should be the case when a nutrients AI is compared with mean intake (13).
More importantly, since publication of the 1997 recommendations for vitamin D (1), much has been learned regarding the metabolism of vitamin D. Thus, a major problem is that the DRI values shown in Table 1 are out of date with respect to recent evidence, as outlined by these proceedings (12,1417). Indeed, there is now sufficient information to set an EAR (18) and to set one that more accurately reflects the data that, without assurance of sun exposure, a requirement and a subsequent recommendation for vitamin D would be higher than that currently in place. Also, concerns about adverse effects and the level of 25(OH)D associated with toxicity have been addressed (19).
New paradigm for vitamin D metabolism
There are important new findings about vitamin D that deepen our knowledge of its role in calcium metabolism (i.e., calciotropic functions) and broaden our understanding of its roles in other pathways (i.e., noncalciotropic functions). In addition, new data show the relationships of sun exposure to status and explain the role of diet in maintaining status. Status continues to be defined primarily by the level of serum 25-hydroxvitamin (12,15) that is synthesized from vitamin D obtained either through skin synthesis or directly from ingestion (Fig. 1). As indicated in Figure 2, the exact cutoff values defining "deficiency" and "insufficiency" remain controversial (12,20,21). Having a level of 25(OH)D in the range denoted as "deficiency" only protects against development of rickets and osteomalacia, whereas a level of 25(OH)D in the range denoted as "insufficiency" is not high enough to offer protection from many chronic diseases (Fig. 3) (12,16,17,20,22,23).
|
|
|
The renal and nonrenal production of 1,25(OH)2D is illustrated in Figure 4. Synthesis of 1,25(OH)2D occurs via the classical renal pathway (proximal tubule epithelial cells) or in several other cell types (other epithelial cells, monocytes, antigen presenting cells) (21). These cells contain the enzyme necessary to add a hydroxyl to 25(OH)D at the one position, the 1-
-hydroxylase, but differ in whether they have vitamin D receptor and inducible 24-hydroxyase (21). Availability of 25(OH)D is critical, and there are 3 conditions that may limit this. First, there must be synthesis of vitamin D in the skin, where previtamin D-3 is converted to vitamin D-3 in the presence of ultraviolet B radiation (Fig. 1). Sunscreens, staying indoors, and living at high latitudes impose a limitation of this route of synthesis. Second, availability of vitamin D from ingesting foods is quite limited in the North American diet. Vitamin D supplements, as part of multivitamins, calcium supplements, or natural products (e.g., fish oils) are other ways to obtain vitamin D. Recent data suggest that many Americans are consuming inadequate levels of vitamin D (2325). And, finally, adipose tissue may function as a metabolic sink for vitamin D-3 and vitamin D-2, limiting their availability for conversion to 25(OH)D. The main evidence for this is from the observation that obese individuals are more likely to have a vitamin D insufficiency (26).
|
Chronic diseases associated with vitamin D deficiency and insufficiency
The newly described roles for 1,25(OH)2D resulting from its extrarenal production have allowed researchers to understand how vitamin D may be involved in more than calcium and phosphorus metabolism. The production of 1,25(OH)2D in the kidney remains the important source of this active metabolite for intestinal absorption of calcium and phosphate and for bone turnover (i.e., the calciotropic functions). There are convincing arguments to view diseases associated with inadequate vitamin D as short latency and long latency (Fig. 3) (22), and calciotropic functions of vitamin D may be associated with the long latency diseases osteoporosis, hypertension, and sarcopenia (29).
Extrarenal synthesis of 1,25(OH)2D is linked to modulation of immune response, and the regulation of cell differentiation, proliferation, and apoptosis (21). Significant extrarenal 1-hydroxylase activity has been found in skin, hair follicles, adrenal medulla, lymph, brain, pancreatic islets, and colon (21). Hewison and colleagues (21) have hypothesized that the noncalciotrophic actions of vitamin D may be those functions for which vitamin D was originally needed in early evolution, i.e., functions related to immune defense, including provisions of barrier integrity for immune surveillance. These newly discovered functions help explain the association between 25(OH)D levels and/or sunlight exposure and many chronic diseases not normally associated with calciotropic functions of vitamin D, such as type I diabetes, type 2 diabetes, cancer, and multiple sclerosis (12,16,17,29,30).
Studies have demonstrated the important effects of race and ethnicity to significantly lower serum 25(OH)D levels in adults over a range of latitudes in North America and over different seasons (23). Despite a low 25(OH)D status, black men and women have a very well-established higher bone mass and a reduced rate of bone fracture compared with whites of comparable age and gender. In sharp contrast to their white counterparts, however, blacks have a much higher incidence and mortality of specific types of aggressive cancers and autoimmune diseases, including type I diabetes, that may be related to their lower levels of serum 25(OH)D (16,17). Thus, functional indicators for vitamin D should include indicators of its noncalciotropic functions.
There is a surprisingly high prevalence of vitamin D insufficiency in healthy adults living in Canada and the United States, 2 countries that have many foods fortified with vitamin D (23). Median vitamin D intakes of Americans indicate that there is an insufficient amount of vitamin D in foods as typically consumed (24,25). Recent studies showing suboptimal serum levels of 25(OH)D confirm the adverse effects of seasonality and latitude on serum 25(OH)D in healthy younger individuals, findings that previously had only been reported in elderly homebound or institutionalized subjects, and in hospital outpatients in North America (15,23). Therefore, it is critical to set EAR and RDA values for vitamin D to facilitate planning and nutrition education initiatives.
The criteria needed to set an EAR
An EAR is best set using both a static indicator and a functional indicator. The static indicator generally measures the concentration of a nutrient or its metabolite, and the measurement directly or indirectly measures storage of the nutrient. For example, leukocyte concentrations of vitamin C directly measure vitamin C storage in a functional tissue, whereas serum magnesium is a measure of transport of this intracellular nutrient, which is a indirect measure of its stores. As shown in Table 2, several EARs set for vitamins have used both static and functional indicators (3133); however, some EARs were set with only 1 type of indicator.
|
To set an RDA from an EAR, the variation in the requirement estimate (SD) is needed, 2 SD are added to the EAR to obtain the RDA. For most micronutrients, a standard estimate of variance of 20% has been applied (where 1 SD = 10%) (3032). The resulting RDA for vitamin D would be a value > 12.5 µg (500 IU). In setting this higher recommendation, it should be noted that concerns about vitamin D toxicity have been alleviated. Vieth and colleagues (19) initially reported that no adverse effects could be seen at levels twice the current upper level of 50 µg (2000 IU) (1). Heaney et al. (18) extended dosing to 250 µg (10,000 IU) and found no adverse effects in men treated for 5 mo.
It is well established that serum 25(OH)D is the best static indicator of vitamin D, because levels of vitamin D itself, from skin synthesis or absorbed from diet is rapidly cleared from blood within 24 h (12,29). Circulating levels of serum 1,25(OH)2D are largely synthesized in the kidney, under the control of PTH, are influenced by serum calcium and phosphorus levels, and are independent of cutaneous synthesis or intake of vitamin D. What remains controversial is the level at which the cutoff for serum 25(OH)D represents deficiency and insufficiency (Fig. 2). Heaney (22) has provided a useful perspective on this, arguing that, historically, the level of serum 25(OH)D has depended on the level needed to prevent the index diseases rickets and osteomalacia. For those short latency diseases (Fig. 3), a cutoff of 27.5 nmol/L indicates deficiency. In consideration of long latency diseases, such as osteoporosis, diabetes, and cancer, the cutoff for serum 25(OH)D is much higher, perhaps as high as 80 nmol/L. Further, he and others argue that one should not view the cutoff for this metabolite as the level determined using normal ranges, because these may be determined in persons apparently disease free but possibly with inadequate vitamin D status (12,20).
A final note is a concern regarding the measurement of 25(OH)D. There are 2 commonly used commercial methods: a radioimmunoassay method and the competitive protein binding assay. Although both methods claim to recognize the D-2 and D-3 isomers of 25(OH)D, the competitive protein binding assay method yields values that are
30% higher than the radioimmunoassay method, because protein binding assays are nonspecific (35). Therefore, the cutoff values for 25(OH)D used to define vitamin D status must be defined in terms of appropriate assay methods.
Having functional indicators for vitamin D would make setting an EAR more precise and would allow determination of tissue needs beyond those of the skeleton. Table 3 provides a list of candidate functional indicators that could be considered for setting the EAR for vitamin D. These include the calciotropic indicators PTH (12,15,20), calcium absorption (33,36), fracture risk (37), blood levels of calcium, phosphorus, and bone turnover markers (38). The most common responsive functional indicator examined to date is the suppression of secondary hyperparathyroidism, based on the calciotropic function of vitamin D in providing enough calcium through active intestinal absorption to suppress PTH levels. Thus, calcium absorption itself can also serve as a functional indicator; Heaney et al. (36) have shown that calcium absorption is 65% higher when serum 25(OH)D is raised from 50 nmol/L to 80 nmol/L. A number of studies suggest strong correlations between serum 25(OH)D and the various bone markers; however, the responses are variable, making them less desirable candidates to serve as functional markers for vitamin D requirements (38). Muscle strength is poor when 25(OH)D levels are low, and the rationale for this has been the provision of adequate phosphate to muscles, a calciotropic function; however, other mechanisms are possible (39). Functional indicators of noncalciotropic function of vitamin D are less well understood (Table 3); however, research is rapidly progressing in determining the role of vitamin D at the cellular and subcellular level.
|
| FOOTNOTES |
|---|
3 Abbreviations used: 1,25(OH)2D, 1,25 dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D: AI, Adequate Intake; D-2, ergocalciferol; D-3, cholecalciferol; DRI, Dietary Reference Intakes; EAR, Estimated Average Requirement; PTH, parathyroid hormone; RDA, Recommended Dietary Allowance. ![]()
| LITERATURE CITED |
|---|
|
|
|---|
1. Institute of Medicine (1997) Dietary Reference Intakes for Calcium Phosphorus, Magnesium, Vitamin D and Fluoride 1997 National Academy Press Washington, DC.
2. National Research Council (1968) Recommended Dietary Allowances 7th ed. 1968 National Academy Press Washington, DC.
3. National Research Council (1974) Recommended Dietary Allowances 8th ed. 1974 National Academy Press Washington, DC.
4. National Research Council (1980) Recommended Dietary Allowances 9th ed. 1980 National Academy Press Washington, DC.
5. National Research Council (1989) Recommended Dietary Allowances 10th ed. 1989 National Academy Press Washington, DC.
6. Canadian Council on Nutrition (1964) Dietary Standard for Canada 1964 Canadian Bulletin on Nutrition. The Queens Printer Ottawa, Ontario.
7. Committee for the Revision of the Dietary Standards for Canada (1976) Dietary Standard for Canada 1976 Canadian Government Publishing Centre, Supply and Services Canada Ottawa, Ontario.
8. Committee for the Revision of the Dietary Standards for Canada (1983) Recommended Nutrient Intakes for Canadians 1983 Canadian Government Publishing Centre, Supply and Services Canada Ottawa, Ontario.
9. Scientific Review Committee (1990) Nutrition Recommendations 1990 Canadian Government Publishing Centre, Supply and Services Canada Ottawa, Ontario.
10. Committee on Food and Nutrition National Research Council (1941) Recommended allowances for the various dietary essentials. J. Am. Diet. Assoc. 17:565-567.
11. Park, E. A. (1940) The therapy of rickets. J. Am. Med. Assoc. 115:370-379.
12. Hollis, B. W. (2005) Circulating 25-hydroxy vitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J. Nutr. 135:317-322.
13. Institute of Medicine (2000) Dietary Reference Intakes. Applications in Dietary Assessment 2000 National Academy Press Washington, DC.
14. Calvo, M. S., Whiting, S. J. & Barton, C. N. (2005) Vitamin D intake: a global perspective of current status. J. Nutr. 135:310-316.
15. Hanley, D. & Davison, K. S. (2005) Vitamin D insufficiency in North America. J. Nutr. 135:332-337.
16. Harris, S. S. (2005) Vitamin D in type 1 diabetes prevention. J. Nutr. 135:323-325.
17. Gross, M. D. (2005) Vitamin D and calcium in the prevention of prostate and colon cancer: new approaches for the identification of needs. J. Nutr. 135:326-331.
18. Heaney, R. P., Davies, K. M., Chen, T. C., Holick, M. F. & Barger-Lux, M. J. (2003) Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am. J. Clin. Nutr. 77:204-210.
19. Vieth, R., Chan, P. C. & MacFarlane, G. D. (2001) Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am. J. Clin. Nutr. 73:288-294.
20. Lips, P. (2004) Which circulating level of 25-hydroxyvitamin D is appropriate?. J. Steroid Biochem. Molec. Biol. 8990:611-614.
21. Hewison, M., Zehnder, D., Chakraverty, R. & Adams, J. S. (2004) Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. Mol. Cell. Endocrinol. 215:31-38.[Medline]
22. Heaney, R. P. (2003) Long latency deficiency disease: insights from calcium and vitamin D. Am. J. Clin. Nutr. 78:912-919.
23. Calvo, M. S. & Whiting, S. J. (2003) Prevalence of vitamin D insufficiency in Canada and the United States: importance to health status and efficacy of current food fortification and dietary supplement use. Nutr. Rev. 61:107-113.[Medline]
24. Moore, C., Murphy, M. M., Keast, D. R. & Holick, M. F. (2004) Vitamin D intake in the United States. J. Am. Diet. Assoc. 104:980-983.[Medline]
25. Calvo, M. S., Whiting, S. J. & Barton, C. N. (2004) Vitamin D fortification in the U.S. and Canada: current status and data needs. Am. J. Clin. Nutr. (in press).
26. Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z. & Holick, M. F. (2000) Decreased bioavailability of vitamin D in obesity. Am. J. Clin. Nutr. 72:690-693.
27. Trang, H. M., Cole, D. E., Rubin, L. A., Pierratos, A., Siu, S. & Vieth, R. (1998) Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am. J. Clin. Nutr. 68:854-858.[Abstract]
28. Rapuri, P. B., Gallagher, J. C. & Haynatzki, G. (2004) Effect of vitamin D2 and D3 supplement use on serum 25OHD concentration in elderly women in summer and winter. Calcif. Tissue Int. 74:150-156.[Medline]
29. Holick, M. F. (2004) Vitamin D: importance in the prevention of cancers, type I diabetes, heart disease, and osteoporosis. Am. J. Clin. Nutr. 79:362-371.
30. Chiu, K., Chu, A., Go, V. & Soad, M. (2004) Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am. J. Clin. Nutr. 79:820-825.
31. Institute of Medicine (1998) Dietary Reference Intakes for Thiamine, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, Choline 1998 National Academy Press Washington, DC .
32. Institute of Medicine (2000) Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, Carotenoids 2000 National Academy Press Washington DC.
33. Institute of Medicine (2001) Dietary Reference Intakes Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc 2001 National Academy Press Washington, DC.
34. Meier, C., Woitge, H. W., Witte, K., Lemmer, B. & Seibel, M. J. (2004) Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. J. Bone Miner. Res. 19:1221-1230.[Medline]
35. Hollis, B. W. (2000) Comparison of commercially available (125)I-based RIA methods for the determination of circulating 25-hydroxyvitamin D. Clin. Chem. 46:1657-1651.
36. Heaney, R. P., Dowell, M. S., Hale, C. A. & Bendich, A. (2003) Calcium absorption varies with in the reference range for serum 25-hydroxyvitamin D. J. Am. Coll. Nutr. 22:142-146.
37. Sahota, O., Mundey, M. K., San, P., Godber, I. M., Lawson, N. & Hosking, D. J. (2004) The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone 35:312-319.[Medline]
38. Calvo, M. S., Eyre, D. R. & Gundberg, C. M. (1996) Molecular basis and clinical application of biological markers of bone turnover. Endocr. Rev. 17:333-368.[Abstract]
39. Bischoff-Ferrari, H. A., Dietrich, T., Orav, E. J., Hu, F. B., Zhang, Y., Karlson, E. W. & Dawson-Hughes, B. (2004) Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged
60 y. Am. J. Clin. Nutr. 80:752-758.
This article has been cited by other articles:
![]() |
A. J. Rovner and K. O. O'Brien Hypovitaminosis D Among Healthy Children in the United States: A Review of the Current Evidence Arch Pediatr Adolesc Med, June 1, 2008; 162(6): 513 - 519. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Manios, G. Moschonis, G. Trovas, and G. P Lyritis Changes in biochemical indexes of bone metabolism and bone mineral density after a 12-mo dietary intervention program: the Postmenopausal Health Study Am. J. Clinical Nutrition, September 1, 2007; 86(3): 781 - 789. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. W. Seely Calciotropic Hormones in Preeclampsia: A Renewal of Interest J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3402 - 3403. [Full Text] [PDF] |
||||
![]() |
G. Schwalfenberg Not enough vitamin D: Health consequences for Canadians Can Fam Physician, May 1, 2007; 53(5): 841 - 854. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Diaz-Lopez and J. B. Cannata-Andia Supplementation of vitamin D and calcium: advantages and risks Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2375 - 2377. [Full Text] [PDF] |
||||
![]() |
S. J. Whiting and M. S. Calvo Overview of the Proceedings from Experimental Biology 2005 Symposium: Optimizing Vitamin D Intake for Populations with Special Needs: Barriers to Effective Food Fortification and Supplementation J. Nutr., April 1, 2006; 136(4): 1114 - 1116. [Full Text] [PDF] |
||||
![]() |
M. S. Calvo and S. J. Whiting Overview of the Proceedings from Experimental Biology 2004 Symposium: Vitamin D Insufficiency: A Significant Risk Factor in Chronic Diseases and Potential Disease-Specific Biomarkers of Vitamin D Sufficiency J. Nutr., February 1, 2005; 135(2): 301 - 303. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||